The objective of this study was to assess the efficacy of abatacept, adalimumab, and etanercept in pediatric JIA patients through changes in the Physician’s Global Assessment (PGA). We found that the majority of patients saw an improvement in their PGA score. Adverse events were similar across all three biologics, and the most common reason for biologic discontinuation was lack of response to therapy.

This study evaluated the response to adalimumab dose intensification (defined as a change in adalimumab therapy with reinduction or an increase in dosing frequency) in pediatric patients with inflammatory bowel disease.

In this study, we explored factors related to teriparatide completion. We found that patients utilizing VSP services were 62% more likely to complete teriparatide and 49% less likely to drop out of treatment after completing 12 months of teriparatide compared to non-VSP patients. Additionally, most patients (64%) required the use a financial assistance program only available to VSP patients. Smoking status also significantly impacted teriparatide completion.

In this study, we examined patients with osteoporosis prescribed denosumab. We explored the association between treatment lapses and discontinuations with fracture incidence. We also assessed reasons patients incurred a lapse in therapy or discontinued treatment, and discussed the role of the specialty pharmacist in supporting patient adherence and persistence.

The purpose of this initiative was to develop a tool to assess quality in the use of TKIs to manage NSCLC and ultimately track variables such as proper medication use, patient safety and healthcare resource utilization.

This study evaluated how specialty pharmacists manage prescription cannabidiol. Pharmacists play an integral role in medication access, resulting in a high approval rate and all patients being able to access therapy. Due to multiple drug interactions with prescription cannabidiol, pharmacists commonly changed the dose of interacting medications. Patient counseling and support for AE management was also a pharmacists key role found in this study.

The objective of this study was to measure time to medication access for prescription CBD from patient referral to first shipment when insurance approval process is managed by embedded specialty pharmacy team.Median time from initial assessment to first shipment was 7 days (IQR 4-13). Of patients for whom the CPhT helped obtain financial assistance (n = 14, 10%), all had $0 costs after assistance.

In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

This was a single-center, retrospective analysis of persistence on droxidopa for the management of orthostatic hypotension in adults patients. This study also evaluated adherence, patient-reported adverse events and falls as well as healthcare resource utilization.

This study of patients with RMS and ≥3 fills of DMT from a health-system specialty pharmacy evaluated DMT persistence. The probability of remaining persistent for 3 years was 0.51. Non-persistent patients mostly switched to a new DMT (39%), discontinued the DMT (26%) discontinued, or transferred care to a new specialty pharmacy or provider (27%). Specialty pharmacists played a key role in DMT transitions and initiated 7% of DMT discontinuations and 36% of DMT switches.